Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13553MR)

This product GTTS-WQ13553MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13553MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1803MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ2968MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ1940MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ13485MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ12905MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ8686MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ15090MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ7630MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW